HSBC/CALL/MODERNA/140/0.1/20.06.24 | Real-time BOERSE MUENCHEN 12:35:54 13/06/2024 BST | ||
| 0.73 EUR | -6.41% |
|
| Current month | -1.27% | ||
| 1 month | +445.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 0.73 | -6.41% |
| 12/06/24 | 0.78 | -13.33% |
| 11/06/24 | 0.9 | -6.25% |
| 10/06/24 | 0.96 | -21.31% |
| 07/06/24 | 1.22 | -15.86% |
Real-time BOERSE MUENCHEN
Last update June 13, 2024 at 12:35 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | HSBC |
| WKN | HG4AJV |
| ISIN | DE000HG4AJV3 |
| Date issued | 23/06/2022 |
| Strike | 140 $ |
| Maturity | 20/06/2024 (7 Days) |
| Parity | 10 : 1 |
| Emission price | 4.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.1 € |
|---|---|
| Lowest since issue | 0.109 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
147.7
USD
Average target price
145.2
USD
Spread / Average Target
-1.72%
- Stock Market
- Warrants
- Warrant